Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT06896916
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05650632
- Locations
- 🇺🇸
Mayo Clinic Arizona /ID# 251405, Phoenix, Arizona, United States
🇺🇸Highlands Oncology Group - Springdale /ID# 267742, Springdale, Arkansas, United States
🇺🇸Rocky Mountain Cancer Centers - Aurora /ID# 268574, Aurora, Colorado, United States
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05259839
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocio /ID# 242974, Sevilla, Spain
🇺🇸University of Arkansas for Medical Sciences /ID# 243096, Little Rock, Arkansas, United States
🇺🇸Sylvester Comprehensive Cancer Center /ID# 243673, Miami, Florida, United States
Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- TeneoOne Inc.
- Registration Number
- NCT04453397
- Locations
- 🇺🇸
Wake Forest, Winston-Salem, North Carolina, United States
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT03933735
- Locations
- 🇺🇸
University of California San Francisco (UCSF) - Parnassus Heights /ID# 238680, San Francisco, California, United States
🇺🇸Tulane University School of Medicine /ID# 242322, New Orleans, Louisiana, United States
🇺🇸Mayo Clinic - Rochester /ID# 238683, Rochester, Minnesota, United States